Drug Profile
CP 741952
Alternative Names: CP-741,952Latest Information Update: 22 Aug 2007
Price :
$50
*
At a glance
- Originator Pfizer
- Class Obesity therapies
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 31 Jul 2007 Discontinued - Phase-II for Obesity in USA (unspecified route)
- 22 Jun 2007 Pfizer completes a phase II trial in Obesity in USA